Shionogi & Co., Ltd. Unsponsored ADR Q3 2025 Earnings Report

Shionogi & Co., Ltd. Unsponsored ADR EPS Results

• Actual EPS: $0.16
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Shionogi & Co., Ltd. Unsponsored ADR Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Shionogi & Co., Ltd. Unsponsored ADR Announcement Details

• Quarter: Q3 2025
• Date: 1/31/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections. The company has also contributed compounds to HIV therapies, including dolutegravir, through its collaboration with ViiV Healthcare. Its research activities have also included central nervous system and pain-related medicines.

Headquartered in Osaka, Shionogi serves patients and healthcare providers in Japan and international markets through its own operations, subsidiaries and commercial partnerships. The company is led by President and Chief Executive Officer Isao Teshirogi. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)s trade in the United States under the symbol SGIOY and represent an interest in the Japanese-listed company.